GZPHF Stock Chart & Stats
$2.34
$0.20(9.35%)
At close: 4:00 PM EST
$2.34
$0.20(9.35%)
Day’s Range― - ―
52-Week Range$1.99 - $2.64
Previous CloseN/A
Volume300.00
Average Volume (3M)83.00
Market Cap
$5.09B
Enterprise Value$42.54K
Total Cash (Recent Filing)$12.29B
Total Debt (Recent Filing)$17.04B
Price to Earnings (P/E)12.2
Beta0.13
Next Earnings
Aug 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.08%
Share Statistics
EPS (TTM)1.81
Shares Outstanding219,900,000
10 Day Avg. Volume250
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)0.68
Price to Sales (P/S)0.33
P/FCF Ratio-27.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)$10.43B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained TTM revenue growth of ~77% signals durable demand expansion and successful product adoption across its portfolio. Over 2–6 months this strengthens pricing leverage and bargaining power with channels, underpinning future scale benefits if margins and cash conversion improve.
Integrated Business ModelVertical presence across R&D, manufacturing and distribution creates structural advantages: better control of supply, higher capture of value, and cross-selling opportunities. This integration supports resilient revenue streams and long-term competitive positioning in China’s pharma market.
Moderate Leverage And Growing EquityA moderate debt-to-equity (~0.55) and rising equity provide financial flexibility to fund R&D, product launches and capex without excessive default risk. Over months this supports strategic investments and dividend capacity, assuming cash generation stabilizes.
Bears Say
Weak Cash GenerationMaterial weakening in operating cash flow and a negative free cash flow year constrain the company’s ability to internally fund R&D, commercialization and dividends. This raises reliance on external financing and increases execution and earnings-quality risk over the medium term.
Margin CompressionSignificant margin decline despite revenue growth indicates pressure from mix, pricing or cost inflation. Persistently lower gross and EBIT margins reduce return on invested capital and leave less buffer to absorb cyclical costs, weakening sustainable profitability over months.
Declining Return On EquityROE falling from ~12% to ~7–8% shows deteriorating capital efficiency and weaker profit conversion from equity. Over a multi-month horizon this can limit reinvestment returns, constrain organic growth funding and pressure investor confidence if not reversed.
Guangzhou Baiyunshan Pharmaceutical Holdings Company News
GZPHF FAQ
What was Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price range in the past 12 months?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H lowest stock price was $1.99 and its highest was $2.64 in the past 12 months.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap is $5.09B.
When is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date is Aug 22, 2026 which is in 15 days.
How were Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s earnings last quarter?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H released its earnings results on Apr 27, 2026. The company reported $0.163 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H overvalued?
According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price is currently Overvalued.
Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pay dividends?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pays a Semiannually dividend of $0.066 which represents an annual dividend yield of 5.08%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H dividends here
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H have?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 219,900,000 shares outstanding.
What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price movement after its last earnings report?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H reported an EPS of $0.163 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H?
Currently, no hedge funds are holding shares in GZPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.26%
12-Months-Change
Fundamentals
Return on Equity
5.08%
Trailing 12-Months
Asset Growth
17.71%
Trailing 12-Months
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials and their intermediates, alongside natural and biological remedies, serving both the Chinese domestic market and international clientele. The company's operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and Others. Beyond its manufacturing activities, GBPHCL is actively involved in the import, export, wholesale, and retail of both Western and Chinese medicines, as well as medical equipment. The company also develops, manufactures, and sells various consumer goods including beverages, food products, health supplements, pre-packaged foods, dairy items, and diverse pharmaceutical forms such as tablets, capsules, lozenges, and injections, in addition to traditional items like tortoise herb jelly. Furthermore, GBPHCL makes strategic investments in the broader health industry, covering areas like medical services, health management, wellness initiatives, and elderly care. It also provides commercial and advertising solutions. As of December 31, 2021, the company maintained a substantial retail presence, managing 154 chain pharmacies operating under brands like Cai Zhi Lin, Jian Min, GPC Prescription Pharmacy, and Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd, supplemented by an additional 22 independent retail stores. Established in 1997, the company originally operated as Guangzhou Pharmaceutical Company Limited before adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. Its headquarters are situated in Guangzhou, China.
Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) Earnings & Revenues
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
4.52% Mutual Funds
― Other Institutional Investors
91.07% Public Companies and
Individual Investors







